|
pubmed:abstractText |
Renal transplantation in HBsAg+ chronic carriers has a relative low risk of progressive liver disease, with mortality associated with liver disease at 7%. In contrast, HBsAg+ recipients who acquired their disease in the early posttransplant period had a mortality of 60%. HBeAg-positive patients who remain persistently positive are a subgroup with a poor prognosis and should not be offered a renal transplant.
|
